FDA Personnel Moves Signal Continuity Under Commissioner Crawford
Executive Summary
Five top-level FDA personnel appointments implemented July 29 suggest general agency policy will likely go unchanged in the near future
You may also be interested in...
BIO exec heads to FDA
BIO Federal Government Relations Director David Boyer will join FDA as assistant commissioner for legislation March 20. The post was vacated by Patrick Ronan in July when he became chief of staff to then newly confirmed Commissioner Lester Crawford (1"The Pink Sheet" Aug. 1, 2005, p. 3). Boyer's background mirrors Ronan's who also served as BIO government relations director prior to joining FDA. Contrasted with Ronan, who had worked for the House Commerce Committee, Boyer's resume includes senior positions at HHS, most recently as special assistant for oversight in the office of the Assistant Secretary for Legislation...
BIO exec heads to FDA
BIO Federal Government Relations Director David Boyer will join FDA as assistant commissioner for legislation March 20. The post was vacated by Patrick Ronan in July when he became chief of staff to then newly confirmed Commissioner Lester Crawford (1"The Pink Sheet" Aug. 1, 2005, p. 3). Boyer's background mirrors Ronan's who also served as BIO government relations director prior to joining FDA. Contrasted with Ronan, who had worked for the House Commerce Committee, Boyer's resume includes senior positions at HHS, most recently as special assistant for oversight in the office of the Assistant Secretary for Legislation...
COX-2 Backlash? Fewer First-Cycle Approvals Would Signal Tougher FDA
A first-cycle drug approval rate significantly lower than 40% could provide the first sign of an effect of COX-2 inhibitor safety issues on FDA reviews, a report from the contract research organization Parexel states